Risk factors

Huge number of PAH patients miss out on combo therapy

A significant proportion of patients with PAH remain undertreated on monotherapy, according to data from an Australian registry. A study of more than 1,000 patients with Group 1 PAH enrolled in the Pulmonary Hypertension Society of Australia and New Zealand Registry found 51% were treated with monotherapy and 49% with combination therapy. Importantly, only 66% ...

Already a member?

Login to keep reading.

© 2021 the limbic